title: Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
abstract: Platelets in therapeutic platelet concentrates are commonly acknowledged to release biologically active constituents during storage. This study examined the influence of photochemical pathogen reduction treatment (PRT) using amotosalen-HCl and UVA light vs. untreated control platelet components, on three factors recently reported to be associated with serious adverse events associated with platelet component (PC) transfusions: sCD40L, IL-27 and sOX40 ligand. Levels of such cytokine-like factors increased significantly during storage, but no significant difference was detected between PRT- and control PCs. This suggests that occurrences of AEs are not directly influenced by PRT but rather may depend on alternate determinants.
authors.affiliation: Université de Lyon, GIMAP-EA3064, Saint Etienne, France.
authors.forename: H
authors.initials: H
authors.lastname: Hamzeh-Cognasse
authors.forename: S
authors.initials: S
authors.lastname: Laradi
authors.forename: J C
authors.initials: JC
authors.lastname: Osselaer
authors.forename: F
authors.initials: F
authors.lastname: Cognasse
authors.forename: O
authors.initials: O
authors.lastname: Garraud
mesh_terms: D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects*; D058731:Blood Safety / Q000009:adverse effects / Q000379:methods*; D023201:CD40 Ligand / Q000378:metabolism*; D011564:Furocoumarins / Q000494:pharmacology*; D006801:Humans; D053278:OX40 Ligand / Q000378:metabolism*; D017713:Platelet Transfusion / Q000009:adverse effects; D014466:Ultraviolet Rays
chemical_list: D011564:Furocoumarins; D053278:OX40 Ligand; D023201:CD40 Ligand; C118577:amotosalen
keywords: cytokine; inflammation; pathogen reduction treatment; platelet storage